ILMN vs RGEN vs BIO Stock Comparison

Illumina, Repligen and Bio-Rad Laboratories Prices as of Nov 13, 2026 Peers: Industry group
ILMN Illumina, Inc.
$207.01 -23.8% 1M +72.6% 1Y
Market cap
$30.20B
P/E
33.7x
Revenue (TTM)
$4.54B
Div. yield
–
Life Sciences Tools Healthcare
4 wins
RGEN Repligen Corp
$167.79 -5.8% 1M +11.4% 1Y
Market cap
$9.36B
P/E
–
Revenue (TTM)
$805.61M
Div. yield
–
Life Sciences Tools Healthcare
3 wins

Head to Head

11 decided of 12

Illumina leads on 4 of the 12 questions below (Illumina 4, Bio-Rad Laboratories 4, Repligen 3). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionILMNRGENBIOLeader
Larger companyMarket capitalisation $30.20B $9.36B $9.74B ILMN
Cheaper on earningsLower P/E, profitable companies only 33.7x -793.0x 9.5x BIO
Cheaper on forward earningsLower price / next fiscal year consensus EPS 40.9x 86.0x 36.0x BIO
Faster revenue growthRevenue growth, trailing twelve months +5.8% +13.8% +1.4% RGEN
More profitableNet margin, trailing twelve months 19.7% -1.5% 39.5% BIO
Better return on capitalReturn on invested capital 16.6% 0.0% -0.6% ILMN
Less leveragedLower net debt / EBITDA 0.4x -2.8x — RGEN
Higher dividend yieldTrailing dividend yield 0.00% 0.00% 0.00% –
Better 1-year returnPrice return, last 12 months +72.6% +11.4% +15.5% ILMN
Better 5-year returnAnnualised price return, 5 years -11.1%/yr -8.3%/yr -13.5%/yr RGEN
Less volatileAnnualised volatility, 1 year 51.1% 46.5% 36.5% BIO
Higher overall scoreMean of the five percentile scores vs peers 75/100 58/100 70/100 ILMN

Percentile Scorecard

ILMNRGENBIO

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisILMNRGENBIO
Valuation 63 #91 of 243 56 #108 of 243 85 #38 of 243
Growth 73 #63 of 228 30 #161 of 228 48 #120 of 228
Profitability 98 #5 of 222 67 #75 of 222 70 #67 of 222
Financial Health 57 #107 of 248 80 #50 of 248 66 #85 of 248
Shareholder Returns 85 #25 of 158 57 #68 of 158 80 #32 of 158
Overall 75 58 70
  • ILMN ranked among 252 companies in Medical Devices and Diagnostics
  • RGEN ranked among 252 companies in Medical Devices and Diagnostics
  • BIO ranked among 252 companies in Medical Devices and Diagnostics

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodILMNRGENBIOSPY
1 month -23.8%-5.8%+1.0% -2.0%
3 months +8.4%+0.6%+2.8% -2.8%
6 months +45.2%+63.1%+47.9% +2.0%
Year to date +57.8%+2.4%+20.8% +10.6%
1 year +72.6%+11.4%+15.5% +12.2%
3 years +118.3%+9.1%+19.1% +68.1%
3 years, per year +29.7%+2.9%+6.0% +18.9%
5 years -44.5%-35.1%-51.6% +61.4%
5 years, per year -11.1%-8.3%-13.5% +10.1%
10 years +54.5%+419.6%+119.6% +248.5%
10 years, per year +4.4%+17.9%+8.2% +13.3%

Risk

MeasureILMNRGENBIOSPY
Volatility, 1Y 51.1%46.5%36.5% 13.6%
Downside volatility, 1Y 50.9%47.4%35.6% 13.9%
Beta vs S&P 500, 1Y 1.111.210.75 1.00
Return / volatility, 1Y 1.420.250.43 0.90
Max drawdown, 5Y -82.9%-64.7%-72.2% -25.4%
From 52-week high -29.5%-13.8%-6.2% -3.2%
52-week high $293.69$194.57$390.34 $779.14
52-week low $114.44$102.87$241.71 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleILMNRGENBIO
P/E now vs peer median 34.9xmedian 26.5x -804.0xmedian 26.5x 9.6xmedian 26.5x
P/S now vs peer median 6.9xmedian 2.7x 11.8xmedian 2.7x 3.8xmedian 2.7x
EV/EBITDA now vs peer median 25.7xmedian 18.4x 83.9xmedian 18.4x —median 18.4x
P/FCF now vs peer median 29.6xmedian 25.4x 89.1xmedian 25.4x 29.9xmedian 25.4x
P/B now vs peer median 10.0xmedian 2.5x 4.5xmedian 2.5x 1.3xmedian 2.5x
PEG now vs peer median 0.85median 0.98 28.28median 0.98 0.09median 0.98

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsILMNRGENBIO
Revenue $4.54B $805.61M $2.59B
Gross profit $3.08B $430.67M $1.33B
Operating income $960.00M $18.24M -$61.90M
Net income $895.00M -$11.80M $1.02B
Free cash flow $1.06B $106.72M $329.10M
R&D $975.00M $57.23M $265.80M
EPS (diluted) $5.81 $-0.21 $37.96
Cash & equivalents $1.29B $726.96M $465.30M
Total debt $1.79B $555.60M $1.20B
Shares (diluted) 154.00M 56.56M 26.95M
Enterprise value $24.91B $6.14B $3.35B

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricILMNRGENBIO
P/E 34.9x -804.0x 9.6x
P/FCF 29.6x 89.1x 29.9x
P/Operating cash flow 25.4x 73.2x 21.0x
P/S 6.9x 11.8x 3.8x
P/B 10.0x 4.5x 1.3x
P/Tangible book 11.4x 5.3x 1.3x
EV/EBITDA 25.7x 83.9x –
EV/EBIT 33.1x 504.7x -151.6x
EV/Revenue 7.0x 11.4x 3.6x
EV/FCF 30.0x 86.3x 28.5x
EV/Operating cash flow 25.8x 70.9x 20.1x
PEG (3Y EPS CAGR) 0.85 28.28 0.09

Growth

14 metrics
MetricILMNRGENBIO
Revenue growth (1Y) 5.8% 13.8% 1.4%
Revenue CAGR (3Y) -0.7% 7.3% -1.6%
Gross profit growth (1Y) 8.5% 33.0% -0.6%
Gross profit CAGR (3Y) 4.4% 13.3% -3.0%
Operating income growth (1Y) 23.1% 2,185% -127.6%
Operating income CAGR (3Y) 30.0% -40.5% -29.5%
Net income growth (1Y) 27.5% -779.2% 251.3%
Net income CAGR (3Y) 40.9% -28.4% 103.5%
EPS growth (1Y) 27.5% -778.9% 251.2%
EPS CAGR (3Y) 41.2% -28.4% 107.7%
Operating cash flow growth (1Y) 9.6% -0.8% -4.8%
Operating cash flow CAGR (3Y) 47.5% 5.3% 7.8%
Free cash flow growth (1Y) 5.7% -3.0% -2.3%
Free cash flow CAGR (3Y) 126.5% 17.6% 13.6%

Profitability

14 metrics
MetricILMNRGENBIO
Gross margin 67.9% 53.5% 51.3%
EBITDA margin 27.3% 13.6% –
Operating margin 21.2% 2.3% -2.4%
Pretax margin 23.3% 1.0% 50.9%
Net margin 19.7% -1.5% 39.5%
FCF margin 23.3% 13.2% 12.7%
Operating cash flow margin 27.1% 16.1% 18.1%
Return on equity 29.9% -1.7% 13.8%
Return on assets 13.3% -1.2% 9.7%
Return on invested capital 16.6% 0.0% -0.6%
Return on capital employed 17.2% 0.6% -0.6%
Asset turnover 0.7x 0.3x 0.2x
Cash conversion (OCF / net income) 1.4x -11.0x 0.5x
Stock comp / revenue 5.9% 4.2% 2.4%

Financial Health

11 metrics
MetricILMNRGENBIO
Debt / assets 26.3% 19.0% 11.2%
Debt / equity 0.6x 0.3x 0.2x
Net debt / EBITDA 0.4x -2.8x –
Debt / FCF 1.7x 5.2x 3.7x
Liabilities / assets 53.8% 28.5% 29.5%
Equity / assets 46.2% 71.5% 70.5%
Interest coverage 9.8x 0.8x -1.3x
Current ratio 2.6x 9.9x 3.2x
Quick ratio 1.8x 8.1x 2.2x
Cash ratio 1.2x 6.9x 1.7x
Altman Z-score 6.62 7.80 3.41

Shareholder Returns

7 metrics
MetricILMNRGENBIO
Dividend yield – – –
Net buyback yield 1.2% -0.2% 0.7%
Shareholder yield 1.2% -0.2% 0.7%
Payout ratio (earnings) – – –
Payout ratio (FCF) – – –
Dividend growth (1Y) – – –
Dividend CAGR (3Y) – – –

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusILMNRGENBIO
Forward P/E 40.9xFY2026 86.0xFY2026 36.0xFY2026
EPS, next fiscal year $5.06FY2026 $1.95FY2026 $10.18FY2026
EPS growth, next FY +4.5%FY2026 +14.0%FY2026 +2.6%FY2026
EPS growth, the year after +25.1% +29.2% -0.2%
Revenue, next fiscal year $4.53BFY2026 $791.31MFY2026 $2.69BFY2026
Revenue growth, next FY +4.4%FY2026 +7.2%FY2026 +4.2%FY2026
Revenue growth, the year after +12.6% +44.3% -7.4%

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersILMNRGENBIO
Held by institutions 100.0% 100.0% 89.5%
Institutions holding 935 483 405
Change in shares held, QoQ +0.0% +1.2% -2.9%
Institutions buying 464 273 177
Institutions selling 331 141 157
Buyers to sellers 1.40 1.94 1.13

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

ILMNRGENBIO
ILMN 1.00 0.48 0.35
RGEN 0.48 1.00 0.53
BIO 0.35 0.53 1.00

Add a Peer

Largest companies in the same industry

Related Comparisons

Frequently Asked Questions

Which is bigger, ILMN, RGEN and BIO?

Illumina (ILMN) is the largest by market capitalisation: Illumina (ILMN) $30.20B, Repligen (RGEN) $9.36B, Bio-Rad Laboratories (BIO) $9.74B.

Which stock is cheaper, ILMN, RGEN and BIO?

Bio-Rad Laboratories (BIO) trades on the lowest price-to-earnings ratio (Illumina (ILMN) 33.7x, Repligen (RGEN) -793.0x, Bio-Rad Laboratories (BIO) 9.5x). On next year's consensus earnings, Bio-Rad Laboratories (BIO) is cheapest (Illumina (ILMN) 40.9x, Repligen (RGEN) 86.0x, Bio-Rad Laboratories (BIO) 36.0x). A lower multiple can reflect slower expected growth, so read it next to the growth figures.

Which company is growing faster?

Repligen (RGEN) grew revenue fastest over the trailing twelve months: Illumina (ILMN) +5.8%, Repligen (RGEN) +13.8%, Bio-Rad Laboratories (BIO) +1.4%.

Which company is more profitable?

Bio-Rad Laboratories (BIO) has the highest net margin (Illumina (ILMN) 19.7%, Repligen (RGEN) -1.5%, Bio-Rad Laboratories (BIO) 39.5%). On return on invested capital, Illumina (ILMN) leads (Illumina (ILMN) 16.6%, Repligen (RGEN) 0.0%, Bio-Rad Laboratories (BIO) -0.6%).

Which stock has performed better?

Over the past year Illumina (ILMN) returned the most: Illumina (ILMN) +72.6%, Repligen (RGEN) +11.4%, Bio-Rad Laboratories (BIO) +15.5%. Over five years, Repligen (RGEN) compounded fastest (Illumina (ILMN) -11.1%/yr, Repligen (RGEN) -8.3%/yr, Bio-Rad Laboratories (BIO) -13.5%/yr). Returns are price only, before dividends.

Which stock is riskier?

By one-year price volatility, Bio-Rad Laboratories (BIO) has been the steadiest (Illumina (ILMN) 51.1%, Repligen (RGEN) 46.5%, Bio-Rad Laboratories (BIO) 36.5%). Volatility measures how widely the price swings, not the risk of the business.

Which is the better stock, ILMN, RGEN and BIO?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, Illumina (ILMN) leads on 4. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.